[Local antitumor treatments].
The idea of intraoperative adjuvant treatment is not new. This review describes only the strategies studied in phase III clinical trials. Among these strategies, only Gliadel® obtained marketing authorization. Some immunotoxins, administered by convection-enhanced delivery, and a gene therapy approach using an adenovirus went through a phase II trial and are currently being studied in a phase III trial. Brachytherapy has never been validated by a clinical trial.
Menei
P
P
Département de neurochirurgie, CHU d'Angers, 4, rue Larrey, 49940 Angers cedex 9, France. phmenei@chu-angers.fr
Metellus
P
P
D001672:Biocompatible Materials; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000628:therapy; D002330:Carmustine; D017326:Clinical Trials, Phase III as Topic; D003652:Decanoic Acids; D005909:Glioblastoma / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D011091:Polyesters
D001672:Biocompatible Materials; D003652:Decanoic Acids; D011091:Polyesters; C055401:decanedioic acid-4,4'-(1,3-propanediylbis(oxy))bis(benzoic acid) copolymer; D002330:Carmustine